Vol. 14, Issue 5 (2025)

Author(s):
Shreya Gunjal, Rohan Gugaliya, Bhavana Hiray, Varsha Wadalkar and Sanjay Patil

Abstract:
Thernemergence of stimuli-responsive nanomedicine has transformed cancer therapy byrnenabling precise drug delivery and controlled release mechanisms. Nanocarriersrndesigned to respond to biological (pH, enzymes and redox conditions) orrnexternal (temperature, light, ultrasound, magnetic fields) stimuli enhance drugrntargeting, minimize systemic toxicity, and improve therapeutic efficacy. Thesernadvanced drug delivery systems leverage nanotechnology to optimize the pharmacokineticsrnand bioavailability of chemotherapeutic agents, overcoming barriers such asrnpoor tumor penetration and multidrug resistance. Several nanoparticle-basedrnformulations have gained clinical approval, underscoring their potential inrnoncology. However, challenges persist, including premature drug release,rnbiocompatibility concerns, and regulatory complexities. Future research aims tornrefine multi-stimuli-responsive systems to achieve greater specificity, enhancerntumor microenvironment interaction, and facilitate combination therapies. Thisrnarticle highlights the mechanisms, benefits, and challenges ofrnstimuli-responsive nanomedicine, offering insights into its evolving role inrnpersonalized cancer treatment and precision medicine.